Quality Investor
MarketsPortfolioEvidenceTestedCompareWatchlistAbout 

Pacira BioSciences, Inc.

Rank #100Capital ReturnWatchlistCompare with other stocks

PCRX · Nasdaq · Healthcare

Pacira BioSciences, Inc. (PCRX) — Rank #100 by gross profitability (GP/assets 0.46) · ROE 1.0% · Piotroski F-Score 8 / 9.

As-of 2026-10-30 · CIK 0001396814 · all metrics point-in-time as of the filing date.

About

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

Show more

The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc.

was incorporated in 2006 and is headquartered in Brisbane, California.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
State
DE
Filer Category
Large accelerated filer
Fiscal Year End
December 31
Website
pacira.com

Company Snapshot

P/E and reverse DCF are the primary valuation lenses at this stage.

Market Cap

—

P/E (annual)

—

P/S (annual)

—

P/B

—

P/OCF (annual)

—

Shareholder Yield

—

Employees

825

Industry

Drug Manufacturers - Specialty & Generic

Exchange

Nasdaq

11/12

Flags passed

PCRX fails 1 critical flag

Passes 11 of 12 quality flags

  • FAIL
    Balance sheet deteriorating

    Net cash collapsed with receivables or inventory outpacing revenue

  • PASS
    Gross margin holding
  • PASS
    Dilution within 2%
  • PASS
    FCF not negative from investment
  • PASS
    Disclosure consistent
  • PASS
    Revenue not declining
  • PASS
    Operating margin holding
  • PASS
    Free cash flow intact
  • PASS
    Passes safety gate
  • PASS
    No competitive retreat
  • PASS
    SBC not compressing margin
  • PASS
    No valuation convergence

Strengths Sequential beat (rev + EPS)

A count of the 12 warning flags that could be evaluated. Unweighted: colour follows the worst flag.

Quality Profile

Profitability

1/1 pass
GP / assets
0.46
Return on equity
1.0%
Gross margin trend
PASS

Safety

1/1 pass
Balance-sheet safety
PASS
Debt / equity
0.85
Current ratio
5.04×
Net cash
-$112.09M

Cash Flow

3/3 pass
Positive FCF
PASS
Cash-backed earnings
PASS
Accruals healthy
PASS
SBC / revenue
7.9%

Growth

2/2 pass
Revenue growth
3.6%
Piotroski F-Score
8 / 9
Share dilution
-2.6%

FCF yield, shareholder yield, and buyback activity are the primary reads at this stage.

Profitability

Does it make money well?

No warning flags · GP/assets 0.46

Gross profitability (GP / assets)

0.46

Primary signal (Novy-Marx).

6th of 12 SIC 2834 peers

Return on equity

1.0%

Gross margin

79.4%

6th of 12 SIC 2834 peers

Revenue growth (YoY)

3.6%

Gross margin improving

Margin trend vs prior year.

PASS

Operating Leverage

2022202320242025
Revenue vs COGS
Revenue vs OpEx
Op. Income vs Revenue

Growth

Revenue CAGR (3Y)

2.9%

Revenue CAGR (5Y)

11.1%

Earnings CAGR (3Y)

-23.8%

FCF CAGR (3Y)

5.9%

Cash Flow Health

Is the cash real?

No warning flags · FCF 1843% above net income

Free cash flow

$136.66M

Operating cash flow minus capex.

Positive free cash flow

PASS

FCF vs net income

1842.9%

(FCF − net income) ÷ |net income|. Positive: cash above earnings. Negative: below.

FCF not below net income

Fails when free cash flow is below net income (yellow flag).

PASS

Accruals healthy

Cash-backed earnings.

PASS

SBC / revenue

7.9%

Stock-based comp intensity.

Balance Sheet Strength

Can it survive a storm?

Warning: Balance sheet deteriorating · net debt $112.09M, F-Score 8/9

Balance-sheet safety

Composite anti-fragile check.

PASS

Debt / equity

0.85

8th of 12 SIC 2834 peers (best = lowest)

Current ratio

5.04×

1st of 12 SIC 2834 peers

Quick ratio

3.14×

Net cash

-$112.09M

Cash & equivalents minus total debt.

Piotroski F-Score

8 / 9

Fundamental-strength score (0-9).

Valuation

Is the price reasonable?

No warning flags

Capital allocation quality

Composite score

3.3 / 5

Good
Share count trend(net buybacks)
-2.6%4/5 Strong
Buyback timing
N/AN/A
Dividend growth consistency(non-payer or broken streak)
0 yr3/5 Good
Net debt trajectory
0.0%3/5 Good

Lifecycle Phase History

20202025
Value
Hypergrowth
Capital Return

Price History

PCRX-55.5% · -14.9% CAGRSPY+82.9% · +12.8% CAGR

View full financial statements →

Source filings on SEC EDGAR: 10-K annual reports · 10-Q quarterly reports